Janssen Pharmaceutica (hypoxia-inducible factor) Overview

  • Status
  • Acquired/​Merged

  • Latest Deal Type
  • Asset Purch.

  • Financing Rounds
  • 1

Janssen Pharmaceutica (hypoxia-inducible factor) General Information

Description

A portfolio of preclinical compounds. The portfolio consists of AKB-5169 and other pharmaceutical compounds which are used in development as an oral treatment for inflammatory bowel disease (IBD).

Contact Information

Ownership Status
Acquired/Merged
Financing Status
Corporate Backed or Acquired
Corporate Office
  • Beerse
  • Belgium
Primary Industry
Buildings and Property
Other Industries
Discovery Tools (Healthcare)
Corporate Office
  • Beerse
  • Belgium

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Janssen Pharmaceutica (hypoxia-inducible factor) Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Janssen Pharmaceutica (hypoxia-inducible factor)‘s full profile, request access.

Request a free trial

Janssen Pharmaceutica (hypoxia-inducible factor) Former Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore Janssen Pharmaceutica (hypoxia-inducible factor)‘s full profile, request access.

Request a free trial

Janssen Pharmaceutica (hypoxia-inducible factor) FAQs

  • Where is Janssen Pharmaceutica (hypoxia-inducible factor) headquartered?

    Janssen Pharmaceutica (hypoxia-inducible factor) is headquartered in Beerse, Belgium.

  • What industry is Janssen Pharmaceutica (hypoxia-inducible factor) in?

    Janssen Pharmaceutica (hypoxia-inducible factor)’s primary industry is Buildings and Property.

  • Is Janssen Pharmaceutica (hypoxia-inducible factor) a private or public company?

    Janssen Pharmaceutica (hypoxia-inducible factor) is a Private company.

  • What is the current valuation of Janssen Pharmaceutica (hypoxia-inducible factor)?

    The current valuation of Janssen Pharmaceutica (hypoxia-inducible factor) is .

  • What is Janssen Pharmaceutica (hypoxia-inducible factor)’s current revenue?

    The current revenue for Janssen Pharmaceutica (hypoxia-inducible factor) is .

  • Who are Janssen Pharmaceutica (hypoxia-inducible factor)’s investors?

    Johnson&Johnson Innovative Medicine has invested in Janssen Pharmaceutica (hypoxia-inducible factor).

  • When was Janssen Pharmaceutica (hypoxia-inducible factor) acquired?

    Janssen Pharmaceutica (hypoxia-inducible factor) was acquired on 13-Feb-2017.

  • Who acquired Janssen Pharmaceutica (hypoxia-inducible factor)?

    Janssen Pharmaceutica (hypoxia-inducible factor) was acquired by Akebia Therapeutics.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process